Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019/2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
暂无分享,去创建一个
Wen-Sen Lee | W. Ko | P. Shao | C. Liao | P. Hsueh | Fu-Der Wang | W. Sheng | Zhi-Yuan Shi | Yen-Hsu Chen | Min-Chi Lu | Y. Chen | Chang-Pan Liu | M. Yen | Ting-Shu Wu | Chun-Ming Lee | Yu-Lin Lee | Lih-Shinn Wang | P. Lu | Shu-Hsing Cheng | S. Tseng | H. Tsai | Chi-Ying Lin | Yu-hui Chen | Po‐Yu Liu
[1] F. Xue,et al. Real-time PCR for the rapid detection of vanA, vanB and vanM genes. , 2020, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[2] I. Morrissey,et al. In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017 , 2019, Antimicrobial Agents and Chemotherapy.
[3] Yu Zhou,et al. Molecular characterization of vancomycin-resistant enterococci isolated from a hospital in Beijing, China. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[4] M. Dowzicky,et al. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016. , 2019, Journal of global antimicrobial resistance.
[5] Ronald N. Jones,et al. Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016 , 2019, Open forum infectious diseases.
[6] M. Huband,et al. Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016) , 2019, Antimicrobial Agents and Chemotherapy.
[7] Luísa Peixe,et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[8] M. Pfaller,et al. Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015) , 2017, Antimicrobial Agents and Chemotherapy.
[9] Hsin-Yi Lin,et al. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] N. Ledeboer,et al. Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant Enterococcus in the Health Care Setting , 2016, Journal of Clinical Microbiology.
[11] Hsin-Yi Lin,et al. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis , 2014, BMC Infectious Diseases.
[12] K. Hegstad,et al. Cluster of linezolid-resistant Enterococcus faecium ST117 in Norwegian hospitals , 2014, Scandinavian journal of infectious diseases.
[13] B. Bozdoğan,et al. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci]. , 2012, Mikrobiyoloji bulteni.
[14] Chun-Eng Liu,et al. Trends in Susceptibility of Vancomycin-Resistant Enterococcus faecium to Tigecycline, Daptomycin, and Linezolid and Molecular Epidemiology of the Isolates: Results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) Study, 2006 to 2010 , 2012, Antimicrobial Agents and Chemotherapy.
[15] H. Barkema,et al. Diagnostic Accuracy Assessment of Sensititre and Agar Disk Diffusion for Determining Antimicrobial Resistance Profiles of Bovine Clinical Mastitis Pathogens , 2011, Journal of Clinical Microbiology.
[16] M. Castanheira,et al. ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries , 2018, The Journal of antimicrobial chemotherapy.
[17] M. Rybak,et al. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. , 2016, The Journal of antimicrobial chemotherapy.